PHARMACEUTICAL COMPOSITION COMPRISING ACTIVATED T CELLS SPECIFIC TO K-RAS FOR PREVENTING AND TREATING LUNG PAPILLARY ADENOCARCINOMA AND METHOD FOR PREPARING SAME
A pharmaceutical composition comprising activated T cells specific to K-ras for preventing and treating lung papillary adenocarcinoma, according to the present invention, uses, as an antigen composition, a K-ras mutant (G12D, G12V, and G13D) recombinant overlapping peptide, which is designed such that a total of 12 epitopes (n= 1 to 12, and the last epitope (n=12) consists of 23 amino acids) in units of 30 amino acids sequentially in the amino acid sequence of K-ras are distinguished, and the sequence of 15 amino acids overlaps between the epitopes. Accordingly, the pharmaceutical composition has an advantageous effect of recognizing and killing lung papillary adenocarcinoma in which K-ras, K-ras mutant G12V, K-ras mutant G12D, or K-ras mutant G13D is detected. Accordingly, the use of the pharmaceutical composition comprising activated T cells specific to K-ras for preventing and treating lung papillary adenocarcinoma of the present invention has the advantage of effectively preventing and treating lung adenocarcinoma, particularly lung papillary adenocarcinoma, in which K-ras as well as K-ras mutants are detected,..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 06. Juli Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
LEE WANG JUN [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-07-06, Last update posted on www.tib.eu: 2023-08-08, Last updated: 2023-08-11 |
|---|
| Patentnummer: |
WO2023128377 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA017656923 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA017656923 | ||
| 003 | DE-627 | ||
| 005 | 20230811085338.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230721s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA017656923 | ||
| 035 | |a (EPA)WO2023128377 | ||
| 035 | |a (EPA)86999547 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a LEE WANG JUN |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a PHARMACEUTICAL COMPOSITION COMPRISING ACTIVATED T CELLS SPECIFIC TO K-RAS FOR PREVENTING AND TREATING LUNG PAPILLARY ADENOCARCINOMA AND METHOD FOR PREPARING SAME |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-07-06, Last update posted on www.tib.eu: 2023-08-08, Last updated: 2023-08-11 | ||
| 520 | |a A pharmaceutical composition comprising activated T cells specific to K-ras for preventing and treating lung papillary adenocarcinoma, according to the present invention, uses, as an antigen composition, a K-ras mutant (G12D, G12V, and G13D) recombinant overlapping peptide, which is designed such that a total of 12 epitopes (n= 1 to 12, and the last epitope (n=12) consists of 23 amino acids) in units of 30 amino acids sequentially in the amino acid sequence of K-ras are distinguished, and the sequence of 15 amino acids overlaps between the epitopes. Accordingly, the pharmaceutical composition has an advantageous effect of recognizing and killing lung papillary adenocarcinoma in which K-ras, K-ras mutant G12V, K-ras mutant G12D, or K-ras mutant G13D is detected. Accordingly, the use of the pharmaceutical composition comprising activated T cells specific to K-ras for preventing and treating lung papillary adenocarcinoma of the present invention has the advantage of effectively preventing and treating lung adenocarcinoma, particularly lung papillary adenocarcinoma, in which K-ras as well as K-ras mutants are detected,. | ||
| 650 | 4 | |a C12N: Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media (microbiological testing media c12q0001000000) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a bio | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a MOON HYOUN JONG |4 aut | |
| 700 | 0 | |a LIM SUN KI |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 06. Juli |
| 773 | 1 | 8 | |g year:2023 |g day:06 |g month:07 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/86999547/publication/WO2023128377A1?q=WO2023128377 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2023 |b 06 |c 07 |
| 951 | |a AR | ||
| 952 | |j 2023 |b 06 |c 07 | ||